XE7C Stock Overview
A clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.53 |
| 52 Week High | US$5.59 |
| 52 Week Low | US$1.07 |
| Beta | 1.93 |
| 11 Month Change | -11.38% |
| 3 Month Change | 26.63% |
| 1 Year Change | 132.11% |
| 33 Year Change | -45.94% |
| 5 Year Change | 112.61% |
| Change since IPO | -99.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| XE7C | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.0% | 1.1% | 1.3% |
| 1Y | 132.1% | -18.5% | 7.9% |
Return vs Industry: XE7C exceeded the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: XE7C exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| XE7C volatility | |
|---|---|
| XE7C Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XE7C's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XE7C's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Mark Erlander | www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers.
Cardiff Oncology, Inc. Fundamentals Summary
| XE7C fundamental statistics | |
|---|---|
| Market cap | €123.06m |
| Earnings (TTM) | -€40.75m |
| Revenue (TTM) | €651.88k |
188.8x
P/S Ratio-3.0x
P/E RatioIs XE7C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XE7C income statement (TTM) | |
|---|---|
| Revenue | US$688.00k |
| Cost of Revenue | US$34.90m |
| Gross Profit | -US$34.21m |
| Other Expenses | US$8.79m |
| Earnings | -US$43.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | -4,973.11% |
| Net Profit Margin | -6,250.73% |
| Debt/Equity Ratio | 0% |
How did XE7C perform over the long term?
See historical performance and comparison